Investor Presentation

(Nasdaq ; TSX: IMV)

July 7, 2020

Forward-looking Statements

  • This presentation contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made.

  • Such forward-looking statements include, but are not limited to, statements regarding the Company's intention to develop a DPX-based vaccine candidate against COVID-19, the Company's belief that the DPX-based platform creates the opportunity for accelerated development and rapid, large-scale production of a COVID-19 vaccine, the Company's belief in the potential efficacy of its DPX-based vaccine against COVID-19, the Company's belief in the benefits of the third-party research and studies in related coronavirus and SARS studies and third-party sequencing data and their applicability to the Company's DPX platform and a DPX platform related vaccine and the Company's anticipated results from its DPX cancer and infectious disease studies. no responsibility to update forward-looking statements in this presentation except as required by law. These forward-looking statements involve known and unknown risks. Such statements should not be regarded as a representation that any of the plans will be achieved.

  • Actual results may differ materially from those set forth in this presentation due to risks and uncertainties affecting the Company and its products. The Company assumes no responsibility to update forward-looking statements in this presentation except as required by law. These forward-looking statements involve known and unknown risks and uncertainties and those risks and uncertainties include, but are not limited to the Company's ability to develop a DPX-based vaccine candidate against the COVID-19 through the successful and timely completion of clinical trials and studies, the receipt of all regulatory approvals by the Company to commence and then continue clinical studies, and, if successful, the commercialization of its proposed vaccine candidate related to COVID-19, the Company's ability to raise sufficient capital to fund such clinical trials and studies and the production of any COVID-19 vaccine, the ultimate applicability of any third-party research and studies in related coronavirus and SARS studies and sequencing, the Company's ability to enter into agreements with the proposed lead investigators to assist in the clinical development on its vaccine candidate related to COVID-19, the Company's ability to collaborate with governmental authorities with respect to such clinical development, the coverage and applicability of the Company's intellectual property rights to any vaccine candidate related to COVID-19, the ability of the Company to manufacture any vaccine candidate related to COVID-19 rapidly and at scale and other risks detailed from time to time in the Company's ongoing filings and in its annual information form filed with the Canadian regulatory authorities on SEDAR aswww.sedar.com and with the United States Securities and Exchange Commission on EDGAR atwww.sec.gov/edgar.

  • Investors are cautioned not to rely on these forward-looking statements and are encouraged to read the Company's continuous disclosure documents which are available on SEDAR and on EDGAR.

Investment Opportunity

First-in-class drug delivery platform DPX

Unique mechanism of action targeting the immune system and enabling precision immunotherapy Clinically-demonstrated activity in both solid and hematologic cancers as well as infectious diseases Excellent safety profile across all clinical studies phase 1 & 2 studies (N=350)

Clinical portfolio focused on unmet medical needs

Lead program with novel cancer target applicable to most tumor types and with great market potential

Positive results from first phase 2 studies in hard-to-treat cancers provide opportunity and de-risk fast path to market Growth opportunities by expanding DPX™ technology applications to other targets and indications (including COVID-19)

Strong corporate position

Upcoming phase 2 updates in oncology

Clinical phase 1 for DPX COVID-19 to be initiated this summer Experienced leadership and recognized partners (Merck, Wistar)

First-in-class drug delivery platform DPX™

Novel Delivery Platform with "NO-RELEASE" mechanism of action (DPX)

No-release of at site of injection forcing active uptake of pharmaceutical ingredients by immune cells over greatly extended period of times (months)

Lipid nanoparticle technology

  • Fully synthetic & easy to manufacture

  • Lyophilized & reconstituted in lipids for injection

  • Simple administration & extended shelf life

Next-generation Precision Immunotherapy

By delivering peptides as information molecules into immune cells without release at the

injection site, DPX enables precise targeting and control of the immune response

  • Highly targeted T and B cell therapies can be generated against cancer cells or pathogens

  • Opens way to next generation precision immunotherapy with increased safety/efficacy promise

Targeted immune Improved duration and

responsewith

Typical immune-response limited in time and potency

5

© 2020 IMV Inc. All rights reserved.

Attachments

  • Original document
  • Permalink

Disclaimer

IMV Inc. published this content on 07 July 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 07 July 2020 12:08:06 UTC